Zymeworks(ZYME) - 2024 Q3 - Quarterly Results

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results • First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers • Preclinical data presented on ZW220 and ZW251 at EORTC-NCI-AACR conference • Our partner Jazz Pharmaceuticals presented new and updated clinical data at ESMO 2024 on zanidatamab highlighting its potential for the treatment of multiple HER2-positive (HER+) indications • Zymeworks to host in-person and virtual R ...